© 2004 by Oxford University Press
© 2004 Oxford University Press
|
|
ARTICLE |
Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
Affiliations of authors: Department of Health Policy and Management, Harvard School of Public Health, Boston, MA (SJG, MCW); Innovus Research Inc., Burlington, Ontario, Canada (MK, DG); Innovus Research (U.S.) Inc., Medford, MA (MCW); Department of Pathology, Columbia University School of Medicine, New York, NY (TCW); Catalan Institute of Oncology, Barcelona, Spain (FXB); Departments of Epidemiology and Oncology, McGill University, Montreal, Quebec, Canada (EF)
Correspondence to: Sue J. Goldie, MD, MPH, Harvard School of Public Health, 718 Huntington Ave., 2nd Fl., Boston, MA 02115-5924 (e-mail: sgoldie{at}hsph.harvard.edu)
Background: Human papillomavirus (HPV) vaccine may be commercially available in a few years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 vaccine in a population with an organized cervical cancer screening program. Methods: A computer-based model of the natural history of HPV and cervical cancer was used to project cancer incidence and mortality, life expectancy (adjusted and unadjusted for quality of life), lifetime costs, and incremental cost-effectiveness ratios (i.e., the additional cost of a strategy divided by its additional clinical benefit compared with the next most expensive strategy) associated with different cancer prevention policies, including vaccination (initiated at age 12 years), cytologic screening (initiated at 18, 21, 25, 30, or 35 years), and combined vaccination and screening strategies. We assumed that vaccination was 90% effective in reducing the risk of persistent HPV16/18 infections and evaluated alternative assumptions about vaccine efficacy, waning immunity, and risk of replacement with non-16/18 HPV types. Results: Our model showed that the most effective strategy with an incremental cost-effectiveness ratio of less than $60–000 per quality-adjusted life year is one combining vaccination at age 12 years with triennial conventional cytologic screening beginning at age 25 years, compared with the next best strategy of vaccination and cytologic screening every 5 years beginning at age 21 years. This triennial strategy would reduce the absolute lifetime risk of cervical cancer by 94% compared with no intervention. These results were sensitive to alternative assumptions about the underlying patterns of cervical cancer screening, duration of vaccine efficacy, and natural history of HPV infection in older women. Conclusions: Our model predicts that a vaccine that prevents persistent HPV16/18 infection will reduce the incidence of HPV16/18-associated cervical cancer, even in a setting of cytologic screening. A program of vaccination that permits a later age of screening initiation and a less frequent screening interval is likely to be a cost-effective use of health care resources.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Andrae, L. Kemetli, P. Sparen, L. Silfverdal, B. Strander, W. Ryd, J. Dillner, and S. Tornberg Screening-Preventable Cervical Cancer Risks: Evidence From a Nationwide Audit in Sweden J Natl Cancer Inst, May 7, 2008; 100(9): 622 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Goldhaber-Fiebert, N. K. Stout, J. A. Salomon, K. M. Kuntz, and S. J. Goldie Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination J Natl Cancer Inst, March 5, 2008; 100(5): 308 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Outterson and A. S. Kesselheim Market-Based Licensing For HPV Vaccines In Developing Countries Health Aff., January 1, 2008; 27(1): 130 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Ortega-Sanchez, G. M. Lee, R. J. Jacobs, L. A. Prosser, N.-A. Molinari, X. Zhang, W. B. Baine, M. M. McCauley, T. Miller, and for the Working Group on Leading Economic Issues f Projected Cost-effectiveness of New Vaccines for Adolescents in the United States Pediatrics, January 1, 2008; 121(Supplement_1): S63 - S78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brisson PhD, N. Van de Velde MSc, P. De Wals MD PhD, and M.-C. Boily PhD Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection Can. Med. Assoc. J., August 28, 2007; 177(5): 464 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Sussman, D. Helitzer, M. Sanders, B. Urquieta, M. Salvador, and K. Ndiaye HPV and Cervical Cancer Prevention Counseling With Younger Adolescents: Implications for Primary Care Ann. Fam. Med, July 1, 2007; 5(4): 298 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Insinga, E. J. Dasbach, E. H. Elbasha, K.-L. Liaw, and E. Barr Incidence and Duration of Cervical Human Papillomavirus 6, 11, 16, and 18 Infections in Young Women: An Evaluation from Multiple Analytic Perspectives Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 709 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Van de Velde, M. Brisson, and M.-C. Boily Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty Am. J. Epidemiol., April 1, 2007; 165(7): 762 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Weller and L. R. Stanberry Estimating the Population Prevalence of HPV JAMA, February 28, 2007; 297(8): 876 - 878. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Carozzi, S. Bisanzi, C. Sani, M. Zappa, S. Cecchini, S. Ciatto, and M. Confortini Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 Assay in Detection of High-Risk Human Papillomavirus and Diagnosis of Biopsy-Confirmed High-Grade Cervical Disease J. Clin. Microbiol., February 1, 2007; 45(2): 364 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Saslow, P. E. Castle, J. T. Cox, D. D. Davey, M. H. Einstein, D. G. Ferris, S. J. Goldie, D. M. Harper, W. Kinney, A.-B. Moscicki, et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors CA Cancer J Clin, January 1, 2007; 57(1): 7 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Schiller and D. R. Lowy Prospects for Cervical Cancer Prevention by Human Papillomavirus Vaccination Cancer Res., November 1, 2006; 66(21): 10229 - 10232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Block, T. Nolan, C. Sattler, E. Barr, K. E.D. Giacoletti, C. D. Marchant, X. Castellsague, S. A. Rusche, S. Lukac, J. T. Bryan, et al. Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women Pediatrics, November 1, 2006; 118(5): 2135 - 2145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Monk and D. J. Wiley Will Widespread Human Papillomavirus Prophylactic Vaccination Change Sexual Practices of Adolescent and Young Adult Women in America? Obstet. Gynecol., August 1, 2006; 108(2): 420 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Dasbach, E. H. Elbasha, and R. P. Insinga Mathematical Models for Predicting the Epidemiologic and Economic Impact of Vaccination against Human Papillomavirus Infection and Disease Epidemiol. Rev., August 1, 2006; 28(1): 88 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Waller, L. A.V. Marlow, and J. Wardle Mothers' Attitudes towards Preventing Cervical Cancer through Human Papillomavirus Vaccination: A Qualitative Study. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1257 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R Schmiedeskamp and D. R Kockler Human Papillomavirus Vaccines Ann. Pharmacother., July 1, 2006; 40(7): 1344 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Pichichero Prevention of cervical cancer through vaccination of adolescents. Clinical Pediatrics, June 1, 2006; 45(5): 393 - 398. [PDF]
|
|
|
|
 |
|
 U. Siebert, G. Sroczynski, P. Hillemanns, J. Engel, R. Stabenow, C. Stegmaier, K. Voigt, B. Gibis, D. Holzel, and S. J. Goldie The German Cervical Cancer Screening Model: development and validation of a decision-analytic model for cervical cancer screening in Germany Eur J Public Health, April 1, 2006; 16(2): 185 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Villa Preventive Vaccines For Human Papillomavirus: Close to Market, Latest Advanced Clinical Trial Results, and Issues Related to Their Introduction Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 279 - 282. [Full Text] [PDF]
|
|
|
|
|
|
A. N. Burchell, H. Richardson, S. M. Mahmud, H. Trottier, P. P. Tellier, J. Hanley, F. Coutlee, and E. L. Franco Modeling the Sexual Transmissibility of Human Papillomavirus Infection using Stochastic Computer Simulation and Empirical Data from a Cohort Study of Young Women in Montreal, Canada Am. J. Epidemiol., March 15, 2006; 163(6): 534 - 543. [Abstract] [Full Text] [PDF]
|
|